Venous thrombosis in patients with high-grade glioma

Current Opinion in Oncology

Volumn 27, Issue 6, 2015, Pages 516-521

  Taillibert, Sophie ^a   Taillandier, Luc ^b,c   Le Rhun, Emilie ^d,e,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f UNIV LILLE   (France)

Author keywords

Brain tumor; Deep venous thrombosis; Glioblastoma; High grade glioma; Pulmonary embolism

Indexed keywords

BEVACIZUMAB; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 8; D DIMER; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PROTHROMBIN; THROMBIN INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

AGE; ANTICOAGULANT THERAPY; BLEEDING TENDENCY; BLOOD GROUP A; BLOOD GROUP AB; BODY MASS; BRAIN SURGERY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; COMPRESSION STOCKING; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; FALL RISK; GLIOMA; HEMIPARESIS; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; HYPERTENSION; INCIDENCE; INFERIOR CAVA VEIN; KARNOFSKY PERFORMANCE STATUS; LEG DISEASE; LEUKOCYTE COUNT; MEDICATION COMPLIANCE; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT INDICATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; BRAIN NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; INTRACRANIAL HEMORRHAGES; RISK FACTOR;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BIOMARKERS; BRAIN NEOPLASMS; GLIOMA; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84944070531     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000226     Document Type: Review

References (68)

1. Mandel JJ, Yust-Katz S, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Clin Oncol 2014; 32:5s. (Suppl; abstr 2033).
2. Edwin NC, Elson P, Ahluwalia MS, Khorana AA. Venous thromboembolism in patients with glioblastoma, risk factors and prognostic importance. J Clin Oncol 2015; 33. (Suppl; abstr e13027).
3. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106:601-608.
4. Smith TR, Nanney AD, Lall RR, et al. Development of venous thromboembolism (VTE) in patients undergoing surgery for brain tumors: results from a single center over a 10 year period. J Clin Neurosci 2015; 22:519-525.
5. Kayser-Gatchalian MC, Kayser K. Thrombosis and intracranial tumors. J Neurol 1975; 209:217-224.
6. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro-Oncol 2007; 9:89-95.
7. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8:221-227.
8. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89:640-646.
9. Chaichana KL, Pendleton C, Jackson C, et al. Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res 2013; 35:206-211.
10. Sawaya R, Auccarello M, Elkaliny M, Nishiyama H. Post operative venous thromboembolism and brain tumors: part 1: clinical profile. J Neurooncol 1992; 14:119-125.
11. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk thromboembolism during treatment high-grade glioma: a prospective study. Eur J Cancer 1997; 33:1592-1596.
12. Anderson F, Huang W, Sullivan C, et al. The continuing risk of venous thromboembolism following operation for glioma: findings from the Glioma Outcomes Project. Thromb Hemost 2001; 86 (Suppl). OC902 (abs).
13. Dickinson H, Carico C, Nuño M, et al. Unplanned readmissions and survival following brain tumor surgery. J Neurosurg 2015; 122:61-68.
14. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13:334-336.
15. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993; 70:393-396.
16. Streiff MB, Segal J, Grossman SA, et al. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004; 100:1717-1723.
17. D'Agoretta D'Alpium Santos Costa D, Romeira D, Fernandes Valente M, et al. Venous thrombotic events in patients with glioblastoma. J Clin Oncol 2015; 33 (Suppl; abstr e13059).
18. Rodas RA, Fenstermaker RA, McKeever PE, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 1998; 89:200-205.
19. Prayson NF, Koch P, Angelov L, Prayson RA. Microscopic thrombi in anaplastic astrocytoma predict worse survival? Ann Diagn Pathol 2011; 15:389-393.
20. Valladares JB, Hankinson J. Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery 1980; 6:138-141.
21. Misch M, Czabanka M, Dengler J, et al. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res 2013; 33:2093-2098.
22. Thaler J, Ay C, Kaider A, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-Oncology 2014; 0:1-7.
23. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8:114-120.
24. Vormittag R, Simanek R, Ay C, et al. High factor VII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176-2181.
25. Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999; 162:4882-4892.
26. Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77:1877-1883.
27. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65:1406-1413.
28. Rong Y, Hu F, Mackman H, et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1 independent mechanisms. Cancer Res 2006; 66:7067-7074.
29. Blum S, Issbruker K, Willuweit A, et al. An inhibitory role of the phosphatidylinositol 3-kinase signaling pathway in VEGF-induced tissue factor expression. J Biol Chem 2001; 276:33428-33434.
30. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumor growth and provide diagnostic biomarkers. Nature Cell Biol 2008; 10:1470-1476.
31. Sartori MT, Della Puppa A, Balin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011; 104:225-231.
32. Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hamostaseologie 2011; 32:127-131.
33. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10:1363-1370.
34. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Practice Guideline Update. J Clin Oncol 2013; 31:2189-2204.
35. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-4907.
36. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7:291-292.
37. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377-5382.
38. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:1-16.
39. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56-70.
40. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59:194-204.
41. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008; 19 (suppl 2):ii126-ii127.
42. Frisisus J, Ebeling M, Karst M, et al. Prevention of venous thromboembolic complications with and without intermittent pneumatic compression in neurosurgical cranial procedures using intraoperative magnetic resonance imaging.
43. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80-85.
44. Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 2001; 94:918-921.
45. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160:2327-2332.
46. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43:1074-1081.
47. Lukassen JNM, Groen JL, Jacobs WC, Vleggeert-Lankamp CLA. Thromboembolic Prophylaxis in Neurosurgical Practice: A Review. J Spine 2014; 4:1-7.
48. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebocontrolled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8:1959-1965.
49. Robins HI, O'Neill A, Gilbert M, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008; 62:227-233.
50. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95:129-134.
51. Kuhn SA, Marosi C, Pabinger I, et al. CoaGlio IV trial: randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV. J Clin Oncol 2015; 33:. (Suppl; abstr TPS2079).
52. Quevedo JF, Buckner JC, Schmidt JL, et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69:329-332.
53. Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol 2010; 23:592-596.
54. Bitoh S, Hasegawa H, Ohtsuki H, et al. Cerebral neoplasms initially presenting with massive intra-cerebral hemorrhage. Surg Neurol 1984; 22:57-62.
55. Lieu AS, Hwang SL, Howng SL, Chai CY. Brain tumors with hemorrhage. J Formos Med Assoc 1999; 98:365-367.
56. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro-Oncology 2012; 14:73-80.
57. Vitale FV, Rotondo S, Sessa E, et al. Low molecular weight heparin administration in cancer patients with hypercoaguability-related complications and carrying brain metastases: a case series study. J Oncol Pharm Pract 2012; 18:10-16.
58. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153.
59. Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43:1111-1114.
60. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost 2014; 40:325-331.
61. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919-4926.
62. Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a populationbased cohort study. Blood 2014; 123:3972-3978.
63. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a metaanalysis. J Am Med Assoc 2008; 300:2277-2285.
64. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
65. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733.
66. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009; 72:1601-1606.
67. Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106:121.
68. Lee A, Kastelan M, Wheeler H. Use of bevacizumab in anticoagulated recurrent glioblastoma multiforme patients: an Australian experience. Ann Oncol 2014; 25 (Suppl 4); iv144, 435P.